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Regulation by CD25 lymphocytes of autoantigen-specific T-cell
responses in Goodpasture’s (anti-GBM) disease.
Background. Goodpasture’s, or anti-glomerular basement
membrane (GBM), disease is unusual among autoimmune dis-
eases in that it rarely follows a relapsing-remitting course.
Moreover, untreated, autoantibodies disappear spontaneously
after 1 to 3 years and, following treatment, autoreactive T cells
diminish in frequency. This suggests that operational tolerance
toward the autoantigen is reestablished. However, the mecha-
nisms underlying this have remained unclear. Recent data have
suggested that a population of regulatory T lymphocytes can
suppress both autoimmune and alloimmune responses in ani-
mal models and are present in normal individuals. However,
to date, they have not been demonstrated to play a role in
human renal autoimmune disease.
Methods. We studied the role of regulatory CD25 cells in
suppressing T-cell responses to the Goodpasture autoantigen
in nine patients with Goodpasture’s disease.
Results. At the time of acute presentation, there was no
evidence of a regulatory cell population. However, from 3
months onward a population emerged, capable of suppressing
the response to the Goodpasture autoantigen. Following deple-
tion of CD25 cells, the frequencies of autoreactive-, GBM-,
or collagen 3(IV)NC1-specific T cells were significantly in-
creased (P  0.031 by paired t test), with five of seven (71%)
convalescent patients and no acute patients demonstrating reg-
ulation.
Conclusion. These data demonstrate that, in Goodpasture’s
disease, regulatory CD25 T cells play a role in inhibiting the
autoimmune response. Their emergence and persistence may
underlie the “single hit” nature of this condition. Understand-
ing the conditions required for the development and propaga-
tion of these cells would allow development of novel therapeu-
tic strategies for inducing hyporesponsiveness in autoimmune
disease.
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Goodpasture’s, or anti-glomerular basement membrane
(GBM), disease is characterized by a rapidly progressive
crescentic glomerulonephritis, associated with pulmonary
hemorrhage in more than one half of cases. Although rare
as a cause of renal failure, it has been extensively studied
as a model of immune-mediated glomerulonephritis and
much is known regarding the pathophysiology of the
disease [1]. Unlike most human autoimmune diseases,
the autoantigen recognized by both T and B lymphocytes
is known, although only the B-cell epitopes have been
convincingly characterized [2–4]. The lymphocytes react
in most cases to determinants within the noncollagenous
domain of the 3 chain of type IV collagen [3(IV)NC1],
termed the Goodpasture antigen [5].
A number of features of this condition separate it from
other human autoimmune diseases. In particular, the
disease does not follow a relapsing-remitting course, with
only occasional clinical relapses being reported in the
literature [6]. Moreover, if left untreated, autoantibodies
diminish spontaneously within 3 years [7] and, following
therapy, the frequency of autoreactive T cells similarly
declines [8]. Finally, autoantibodies are not isolated from
normal individuals and cannot be detected in convales-
cent patients despite intercurrent infectious illnesses (our
unpublished observations). These observations, in paral-
lel with the rarity of the disease, suggest that tolerance
to this autoantigen is generally tightly controlled. Recent
data demonstrating thymic expression of the autoantigen
have suggested that this may mostly occur at the level of
central deletion during the development of the immune
repertoire [8, 9]. However, autoreactive GBM-specific
T cells can be demonstrated among circulating lympho-
cytes from patients with acute disease as well from nor-
mal healthy individuals, and there is a temporal reduc-
tion in frequencies from the time of acute disease [8, 10],
suggesting that peripheral mechanisms of tolerance must
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also be involved in preventing development of disease
and preventing relapses. The reason for the breakdown
in tolerance is unclear and the mechanisms that appear
to reestablish tolerance to the autoantigen are even less
well defined.
We have therefore investigated peripheral tolerance,
involving regulation by antigen-specific CD25 regula-
tory cells, using a combination of limiting dilution analy-
sis (LDA) with mathematical modeling to calculate the
frequencies of different cell populations, as well as more
sensitive enzyme-linked immunosorbent spot (ELISPOT)
analysis. Our data suggest that, following acute disease, a
CD25 population emerges that can efficiently diminish
responsiveness of the GBM-specific effector T cells and
may be responsible for the reestablishment of tolerance.
This mechanism could in part explain the single-hit na-
ture of the disease.
METHODS
The study received local Research Ethics Committee
approval.
Antigen production
Recombinant 3(IV)NC1 was produced in COS-7
cells using diethylaminoethyl (DEAE) dextran-medi-
ated transfection, according to previously published
methods [8, 11, 12], and in 293 cells using the Superfect
transfection reagent, according to manufacturer’s in-
structions (Qiagen, Valencia, CA, USA) and as pre-
viously published [13]. Collagenase-solubilized GBM
(CS-GBM) was produced, as previously described, by
sieving cadaveric human kidneys obtained at necropsy,
and isolating glomeruli [14]. These were disrupted by
sonication and digested with Collagenase I (Sigma,
Poole, UK). Tetanus toxoid was purchased from Evans
Medical Ltd. (Leatherhead, UK). Mumps antigen was
obtained from BioWhittaker (Walkersville, MD, USA).
Patients
Patients presenting with histologically and serologi-
cally confirmed Goodpasture’s disease were venesected
as soon as the diagnosis was confirmed and before the
start of treatment where possible. Patients with an estab-
lished diagnosis of Goodpasture’s disease, followed at
the Renal Unit, Hammersmith Hospital, were vene-
sected at various time points from the onset of their
illness. Some of these patients were in a cohort described
in a previous report, in which the technique of LDA for
measuring the frequencies of autoreactive GBM-specific
T cells was established [8]. The patients’ characteristics
are summarized in Table 1.
Treatment following presentation varied according to
the clinical situation, but usually consisted of daily oral
prednisolone (starting at 60 mg and decreasing weekly
by 10 to 15 mg, until reaching 20 mg and then more
slowly), daily oral cyclophosphamide (2 mg/kg), and
daily or near-daily plasma exchange (4 L exchanges for
14 days). In one patient (patient 2), additional pulsed
methylprednisolone (3 daily pulses of 0.5g) had been
administered at the referring hospital prior to venesec-
tion. Patients had their immunosuppression withdrawn
over 6 months from presentation. Cyclophosphamide
was withdrawn at 1 to 3 months and oral steroids were
discontinued by 6 months in all but two patients. One
patient (patient 2) remained on low doses of steroids for
continued nephrotic range proteinuria. The second patient
(patient 5) was transplanted twice following her end-stage
renal failure and was on steroids as well as azathioprine
and calcineurin inhibitors, at different doses during her
follow-up. Since Goodpasture’s disease is strongly asso-
ciated with human leukocyte antigen (HLA)-DR15 and
HLA-DR4 [1], healthy DR15- or DR4-positive volun-
teers were venesected and their peripheral blood mono-
nuclear cells (PBMC) used as controls.
Cell isolation and enrichment
PBMCs were obtained by separating whole blood us-
ing Lymphoprep (Nycomed, Oslo, Norway) and stored
in liquid nitrogen until required. Patients were tissue
typed using conventional DNA methods. CD4 T cells
and antigen-presenting cells (APC) were purified by im-
munomagnetic depletion as previously described [8].
Cell purity was confirmed by staining with anti-CD4/CD8
and anti-CD3/HLA-DR monoclonal antibodies (Phar-
mingen, San Diego, CA, USA), and flow cytometry was
performed on an EPICS XL flow cytometer (Coulter,
Luton, UK).
Limiting dilution analysis
The LDA assays have been previously described in
detail. Briefly, APC were pulsed overnight at 37C with
medium alone, recombinant 3(IV)NC1 at 5g/mL, CS-
GBM at 20 g/mL, or tetanus toxoid (Evans Medical
Ltd.) at 1:1000 dilution. After washing in phosphate-
buffered saline (PBS), the cells were plated out in complete
medium, RPMI 1640, containing 2 mM l-glutamine, 50
g/mL penicillin and streptomycin (Life Technologies,
Paisley, UK), and 10% human AB serum (North London
Transfusion Centre, London, UK) in round-bottomed
96-well plates (Nunc, Paisley, UK). CD4 T cells were
kept at 4C overnight, then counted and plated out in
doubling dilutions into the 96-well plate; 24 replicates
were plated for each T-cell dilution. The final 24 wells
contained only APC and served as the negative controls.
After 6 days, the wells were pulsed with 1 Ci 3H-thymi-
dine (Amersham, Little Chalfont, UK) for the last 16
hours of incubation. Plates were harvested and counted
on a  counter (Wallac, Milton Keynes, UK).
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Table 1. Patient characteristics
ELISPOT samples: LDA samples:
Patient Agea Gender Presenting features Outcome Time from presentation Time from presentation
1 69 M ARF, DD, PH ESRF — 2 weeks
2 23 M ARF, PH R, CRF 4 years 2 weeks, 3 and 8 months
3 54 F ARF, DD R 14 years 2 weeks, 10 years
4 47 M ARF R, CRF 4 years 2 weeks
5 29 F ARF, PH ESRF 25 years —
6 23 M ARF, PH R 11 years 8 years
7 43 F ARF, PH ESRF 4 months —
8 65 F ARF, DD D 2 weeks —
9 22 M ARF R 3 years —
Abbreviations are: ARF, acute renal failure; DD, dialysis-dependent; PH, pulmonary hemorrhage; ESRF, end-stage renal failure; R, recovered; CRF, chronic
renal failure; D, death; LDA, limiting dilution dialysis; ELISPOT, enzyme-linked immunosorbent spot assay.
aAge shown is that at time of diagnosis
Calculating frequencies and assessing deviation from
single-hit kinetics
Frequencies of the number of CD4 T cells reacting
to each APC preparation were calculated using the modi-
fied score function of the maximum likelihood method,
as described previously [15].
The design of LDA protocols is intended to create
single-hit kinetics (i.e., only a single cell is limiting for
the outcome of interest). When the logarithm of the
proportion of nonresponding wells is plotted against the
responder cell number, a straight-line relationship pass-
ing through the origin results. However, in cases where
mixed populations of responders are utilized, analysis of
LDA curves may reveal a nonlinear relationship be-
tween the fraction of nonresponding wells and cell num-
ber, typically with a zigzag pattern [16–20]. This nonlin-
ear relationship is thought to be due to cell types with
opposing effects interacting in the culture systems. The
decrease in responding wells is thought to be due to a
population of regulatory cells, inhibiting the effectors
[17, 19, 21]. The model that best fits the experimental
data [21, 22] interprets the nonlinear, multiple-hit kinetics
as being due to two cell populations possibly competing
for growth factors, one responding, the other regulating
at low cell numbers and responding at higher cell numbers.
The first cell population, termed the effector cell popula-
tion (E), proliferates with single-hit kinetics; the second
cell population, the regulator cell (R), does not.
Based on this two-cell model, and using published
equations for determining the frequencies of the two
cell types [21], calculation of the effector and regulatory
populations in LDA using acute and convalescent pa-
tient samples was performed using Microsoft Excel, ver-
sion 5, software (Microsoft, Seattle, WA, USA). A non-
linear least-squares method was used to fit the measured
experimental data to the theoretical equation. The objec-
tive function was minimized in four dimensions using a
downhill simplex transformation method followed by a
direction-set method. The direction-set method itera-
tions were terminated when the fractional change in the
function was less than or equal to 0.01%. The 5% signifi-
cance level, as calculated by a chi-squared test statistic,
was used to assess the adequacy of fit of the experimental
data to the model.
In order to compare different individuals and the same
individuals at different time points, the ratio of ef-
fector:regulator cells (E:R) was calculated. Ratios of less
than unity reflect a predominant regulatory population,
while ratios greater than one suggest a predominant pro-
liferative population. Plots of the number of negative
wells (Y axis) against the cell number in culture (X axis)
were plotted for all the LDA assays performed, to visu-
ally assess deviation from linearity.
ELISPOT analysis
The frequency of cytokine-producing GBM-specific
T cells was measured using ELISPOT analysis with
CS-GBM and recombinant 3(IV)NC1 antigens, as has
been previously described [23]. Viable PBMC were enu-
merated using the vital dye Trypan Blue (BioWhittaker).
The ELISPOT assay was adapted to measure interferon-
gamma (IFN-)- and interleukin 10 (IL-10)-secreting cells.
ELISPOT plates (Cellular Technology Limited, Cleve-
land, OH, USA) were coated with capture antibodies
against IFN- (Endogen, Woburn, MA, USA) or inter-
leukin-10 (IL-10) (Pharmingen) in PBS and left over-
night at 4C. The plates were blocked with 1% bovine
serum albumin (BSA)-PBS for 1 hour and then washed
with PBS. Between 2.5 and 5 	 106 PBMC were added
to each well in 100 L of complete RPMI medium (as
above). Control wells contained responder PBMC plus
medium alone. Cells were also tested in duplicate or tripli-
cate against mumps antigen (BioWhittaker), tetanus tox-
oid (Evans Medical Ltd.), CS-GBM, and recombinant
3(IV)NC1. After 48 hours, the plates were washed, bio-
tinylated detection antibody added, and the plates were
left for a further overnight incubation at 4C. After fur-
ther washing, horseradish peroxidase-conjugate (Dako,
Glostrup, Denmark) was added for 2 hours at room tem-
perature. Development was with AEC (Sigma Chemical
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Co., St. Louis, MO). The resulting spots were counted on
a computer-assisted ELISPOT Image Analyzer (Cellular
Technology Limited). The frequencies were then ex-
pressed as IFN--or IL-10-producing cells per million
PBMC.
In additional experiments, putative CD25 regulatory
cells were depleted from the PBMC. Cells were incu-
bated with anti-CD25 monoclonal antibody (Phar-
mingen) for 1 hour at 4C, washed twice, and depleted
using magnetic bead separation according to manufac-
turer’s instructions (Dynabeads, Dynal, Oslo, Norway).
Depletion was confirmed by flow cytometry using di-
rectly conjugated anti-CD4 and anti-CD25 monoclonal
antibodies (Pharmingen) using a FACSCalibur (Becton
Dickinson, San Jose, CA, USA) and analyzed with Cell-
quest software (Becton Dickinson). The change in pep-
tide-specific IFN- or IL-10 frequencies following deple-
tion of CD25 cells compared to predepletion values
was quantified and expressed as the mean value and
standard error of the mean.
RESULTS
Convalescent but not acute patients demonstrate
evidence of GBM-specific regulation in LDA assays
Plots of the logarithm of number of negative wells
against the cell number/well were drawn for each pa-
tient’s LDA. A straight line through the origin indicates
single-hit kinetics, suggesting a solitary population of
responding cells. However, in cases where mixed popula-
tions of responders are present, LDA curves reveal a
nonlinear relationship typically with a zigzag pattern
[16–20]. In the patients with acute disease (N  4), the
response to CS-GBM or purified 3(IV)NC1 demon-
strated predominantly straight lines (Fig. 1A), while in
convalescent patients (N  3, with four measurements)
or HLA-matched (DR15-positive) healthy controls (N
3), nonlinear plots were demonstrated (Fig. 1B and C).
In one convalescent patient (patient 6), the overall re-
sponse to autoantigen was poor, making visual interpre-
tation of his LDA difficult.
Therefore, in order to assess differences in regulatory
cell populations more accurately than by inspection of
the LDA plots, we calculated the frequencies of effectors
(E) and responders (R), based on a validated model
describing nonlinear LDA kinetics. To compare individ-

Fig. 1. Limiting dilution analysis (LDA) reveals that convalescent but not acute patients demonstrate responses to collagenase-solubilized glomeru-
lar basement membrane (CS-GBM) and collagen 3(IV)NC1 that follow nonlinear kinetics. Plots of the logarithm of the fraction of nonresponding
wells against the cell number in the well were graphed. In acute patients (N  4), the CS-GBM- or 3(IV)NC1-specific responses all followed
first-order kinetics, evidenced by a straight line (A ). By contrast, in convalescent patients (N  3), the responses followed zigzag lines, characteristic
of multiple-hit kinetics, shown for patients 2 and 3 (in patient 6, the overall response to CS-GBM was poor making analysis difficult) (B ). In
patient 2, the zigzag response was confined to the CS-GBM and 3(IV)NC1 responses, while response to tetanus toxoid followed a straight line.
A similar pattern demonstrating regulation was seen in healthy control individuals (N  4) (C ).
ual responses we expressed the results as a ratio of the
effector: regulatory cell populations (E:R ratio). Our
calculations demonstrated that the E:R ratio was signifi-
cantly lower in convalescent patients (N  3) and con-
trols (N  3) than in those patients with acute disease
(N  4) (P  0.026, comparing acute against convales-
cent groups, by one way ANOVA test)(Fig. 2A). This
pattern of responses was similar using purified recombi-
nant 3(IV)NC1 antigen (Fig. 2B) (N  1, N  2, and
N  2 for acute, convalescent, and control subjects, re-
spectively) confirming that the response was to the
Goodpasture autoantigen and not other basement mem-
brane constituents. Moreover, two patients had sequen-
tial assays performed, the first at the time of presentation
with acute disease and the second during convalescence,
3 then 8 months (patient 2) or 10 years (patient 3) follow-
ing presentation. In both patients, there was a dramatic
decrease in the E:R ratio (of CS-GBM-specific responses
for patient 2 and 3(IV)NC1-specific responses for pa-
tient 3) between the acute and convalescent samples
(Fig. 2C). Taken together, these data demonstrate the
presence of a population of regulatory autoantigen-spe-
cific T cells during disease convalescence and in healthy
control subjects, which is absent in patients at the time
of disease presentation.
To investigate whether these regulatory cells were a
CD25 population of cells as described in animal models
and normal individuals, we measured the frequency of
CS-GBM- and 3(IV)NC1-specific IFN-- and IL-10-
producing T cells by ELISPOT, prior to and following
CD25 cell depletion.
Convalescent but not acute patients have a circulating
population of GBM-specific CD25 regulatory cells
CD25 cell depletion was successful in all cases, with
over 90% depletion of CD4CD25high cells. Using PBMC
from seven convalescent patients and one acute pa-
tient, the frequency of IFN- producing CS-GBM- and
3(IV)NC1-reactive cells was measured pre- and post-
depletion. IL-10 production pre-and postdepletion was
measured in three convalescent patients.
ELISPOT has been shown to be significantly more
sensitive than LDA [23]; consequently, the frequencies
of CS-GBM-specific T cells were higher than those mea-
sured by LDA (1:270 to 1:4000 for ELISPOT; 1:4700 to
1:123,000 for LDA) [8]. Following CD25 cell depletion,
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Fig. 2. Differences in the effector: responder
(E:R) ratio in patients. The differences in E:R
ratio for (A ) collagenase-solubilized glomeru-
lar basement membrane (CS-GBM)-reactive
cells between acute (N  4) and convalescent
patients (N  3) and healthy controls (N 
3) and (B ) 3(IV)NC1-reactive cells (N  1,
N  2, and N  2, respectively, for acute,
convalescent, and control samples) is shown.
A value less than unity suggests that regula-
tory responses predominate, while a value
greater than unity suggests that proliferative
effector responses predominate. It can be seen
that only in acute patients does the ratio ap-
proach unity and is statistically higher than the
values for convalescent patients [P 0.026, by
one-way analysis of variance (ANOVA)]. The
changes in the E:R ratio in two patients (C )
to CS-GBM (patient 2) or 3(IV)NC1 (pa-
tient 3) over time. There is a dramatic decline
in the E:R ratio from the time of presentation
with acute disease to the convalescent period,
which is apparent as early as 3 months.
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Fig. 3. Changes in the frequencies of colla-
genase-solubilized glomerular basement mem-
brane (CS-GBM)- and collagen 3(IV)NC1-
specific interferon-gamma (IFN-)-producing
T cells following CD25 cell depletion. (A) The
increase in CS-GBM-specific IFN- frequen-
cies following CD25 depletion is shown for pa-
tient 4. Of note, there is little change in the fre-
quencies of tetanus-specific IFN-–producing
cells, demonstrating that the regulation is anti-
gen-specific. (B ) The increase in 3(IV)NC1-
specific and CS-GBM-specific T-cell responses
following CD25 depletion is shown for pa-
tient 7. The response to the CS-GBM and the
recombinant 3(IV)NC1 protein demonstrate
that these responses are autoantigen-specific.
(C) The change in CS-GBM- and 3(IV)NC1-
specific IFN- frequencies for each patient fol-
lowing CD25 depletion is shown. There is a sig-
nificant increase in CS-GBM- and 3(IV)NC1-
specific IFN- frequencies following CD25
cell depletion (left panel, P 0.031, by paired
t test comparing pre-and postdepletion fre-
quencies). Regulation, demonstrated by a pos-
itive slope, can be seen in five out of seven
convalescent patients, while in two convales-
cent patients there is little change (patients 2
and 5) and in one acute patient there is a de-
crease in the frequency to both CS-GBM and
3(IV)NC1 following CD25 depletion (pa-
tient 8) (right panel). Solid lines represent re-
sponse to CS-GBM and dotted lines response
to 3(IV)NC1.
there was a significant increase in the CS-GBM- and
3(IV)NC1-specific frequencies in convalescent patients
(P 0.031 by paired t test comparing pre-and postdeple-
tion frequencies), with five out of seven patients demon-
strating regulation (representative examples shown in
Fig. 3 A and B). Furthermore, this increase in GBM-
reactivity was antigen-specific, since the response to re-
call antigens such as tetanus toxoid or mumps decreased
or did not change following CD25 depletion in all of the
convalescent patients. Only one acute patient (patient
8) was tested by ELISPOT, but she demonstrated no
regulation, confirming the LDA data (Fig. 3C). Further-
more, two convalescent patients (patient 2 at 5 years
following presentation and patient 5 at 25 years following
presentation) demonstrated no regulation of IFN- pro-
duction to CS-GBM following CD25 depletion (Fig. 3C).
One patient (patient 5) had been transplanted twice fol-
lowing her original anti-GBM disease and was taking
immunosuppressive drugs. The second patient (patient
2) developed persistent proteinuria following his original
presentation and has declining renal function. Although
he has had no clinical evidence of relapse, a smoldering
ongoing autoimmune response in his kidney cannot be
ruled out. Interestingly, he originally demonstrated regu-
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lation, but this was lost by the time he was tested 4 years
following his presentation. It can be seen that the efficacy
of these cells as regulators is variable, but in certain
individuals they are capable of significantly suppressing
the autoimmune T-cell response to GBM. Interestingly,
the patients with the lowest IFN- frequencies prior to
depletion were the ones that demonstrated the greatest
degree of regulation (Fig. 3C), and a cut off of 
200
spots/million PBMC significantly separated those assays
in which there was evidence of regulation, from those
where none was demonstrated. In five out of six assays
with predepletion values of 
200 spots/million PBMC
and only one out of five with values 200 spots/million
was there regulation (P  0.0098 by two-tailed chi-
squared test), suggesting that only those patients with
relative hyporesponsiveness to the autoantigen had
CD25-mediated regulation. No change in IL-10-pro-
ducing T-cell frequencies were seen following CD25 cell
depletion in the three patients tested (patients 2, 4, and
5), suggesting that the CD25 cells were not significant
IL-10 producers in these patients.
DISCUSSION
In Goodpasture’s disease, the rarity of disease relapse,
the spontaneous disappearance of autoantibodies, and
the decline in the frequency of autoreactive T cells fol-
lowing therapy suggests that following acute disease
functional tolerance is reestablished to the Goodpasture
antigen, 3(IV)NC1. Numerous potential mechanisms
may underlie this, including deletion of the autoreactive
cells, anergy, or active regulation [24]. Recently, regula-
tory CD25 T cells have been demonstrated to be a
ubiquitous mechanism for modulating both allo- and au-
toimmune responses in vivo and in vitro [25–36] and we
have reported the role of these cells in human kidney
transplant recipients [37]; however, thus far, no role has
been demonstrated for these cells in human renal auto-
immune disease. Therefore, we attempted to define their
role in Goodpasture’s disease, a well-characterized hu-
man autoimmune condition.
Our data clearly demonstrate that over a period of
time from the onset of disease a regulatory population
of cells emerges in some patients, which is capable of
modulating the reactivity of autoantigen-specific T cells.
Furthermore, it appears that CD25 cells found in
PBMC from convalescent patients are capable of acting
as such regulators, as shown in the majority (71%) of
patients. It is of interest that the patients who did not
demonstrate a CD25 regulatory population had a fre-
quency of CS-GBM-reactive T cells that was more than
tenfold higher than those that did. Of the two convales-
cent patients who lacked this regulatory population, one
patient (patient 5) had been transplanted twice for end-
stage renal failure and was taking immunosuppressive
drugs at the time of the ELISPOT assay. Whether the
immunosuppression influenced the generation of a regu-
latory population is uncertain. Although regulatory cell
effects have been demonstrated toward alloantigens in
transplanted recipients while on conventional immuno-
suppressive drugs [37], the effect of these drugs on the
generation of autoantigen-reactive regulatory cells is un-
clear. Alternatively, in this case, it may be that the immu-
nosuppressive drugs rather than regulatory mechanisms
were preventing relapse of anti-GBM disease. The sec-
ond patient (patient 2) did not have clinical signs of
relapsing disease, but after an initially straightforward
response to treatment became proteinuric with declining
renal function and shortly after venesection (at 4 years
following presentation) had an acute infectious disease
associated with a sharp increase in serum creatinine. It
will be of interest to follow the patient and repeat the
assays to see if regulatory populations have reemerged
or if his disease relapses. A single patient venesected
at the time of acute disease also did not demonstrate
regulation by ELISPOT, in keeping with the LDA data.
In three convalescent patients tested, we found no
change in the IL-10–producing GBM-specific T-cell fre-
quencies following CD25 depletion, suggesting that the
CD25 cells were not significant IL-10 producers, at least
in these patients. However, it should be noted that only
one of these patients had evidence of GBM-reactive
CD25 regulatory cells (patient 4). However, we can con-
clude that in our limited sample IL-10 production was
not a phenotypic feature of CD25 T cells. Importantly,
these data and the lack of increase in IFN--frequencies
following CD25 depletion to other peptide antigens such
as tetanus and mumps demonstrate clearly that the in-
crease in IFN- frequencies to autoantigen following
CD25 depletion was not merely as a result of an increase
in the percentage of effector cells in the ELISPOT assay.
The findings of a regulatory cell population in the major-
ity of convalescent patients may go some way toward ex-
plaining the decline in CS-GBM- and 3(IV)NC1-specific
T-cell frequencies that occur from the time of acute dis-
ease presentation. These findings may also explain the
decline in autoantibodies in untreated patients, due to
the loss of T-cell help for B-cell responses, although we
did not have such untreated patients in our study to con-
firm this idea. Based on these findings, we would predict
that those uncommon patients with clinical relapses of
anti-GBM disease would not demonstrate such potent
regulatory phenomena and we are currently seeking to
investigate such patients. Of note and reminiscent of the
findings in transplant recipients [37], those patients with
the lower predepletion IFN- frequencies were the ones
that predominantly demonstrated regulation. We found
a cutoff of 200 spots/million PBMC significantly sepa-
rated those with and without evidence of regulation (P
0.0098, by two-tailed chi-squared test). This may be due
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to the effectiveness of the CD25 regulatory cells or may
reflect the ability of these cells to regulate only in the
presence of a small autoreactive clone size.
The mechanisms underlying the action of these regula-
tory cells remain unclear, although they require activa-
tion through their T-cell receptors. Some reports suggest
cell-cell contact is necessary [25, 33, 38], while others
have reported dependence on suppressive cytokines such
as IL-10 [30]. Although the suppressive effects may be
nonantigen-specific, the required activation through
their T-cell receptor does confer antigen specificity on
the cells [29, 30]. Our data demonstrate that in Goodpas-
ture’s disease they are autoantigen (3(IV)NC1)-spe-
cific, since responses to recall antigens such as mumps
or tetanus did not similarly increase following CD25
depletion. The phenotype of the CD25 regulatory cells
have been reported by a number of groups, including
our own [25, 31, 33, 37, 38]. We found no evidence of
significant IL-10 production by the CD25 cells in the
convalescent patients tested and we did not examine
other suppressive cytokine profiles due to limited cell
numbers; however, others have reported a central role
for such suppressive cytokines [30, 32]. We and others
have previously reported that the CD25 cells express
higher levels of certain tumor necrosis factor (TNF) fam-
ily molecules, such as OX40 and GITR, under resting
conditions than the CD25 counterparts [37, 39] al-
though recent data suggest that a more specific marker
is the product of the foxp3 gene [40, 41, 42], which may
finally allow us to purify the regulatory population in a
more specific fashion.
These findings suggest that, given the ability to expand
an autologous regulatory cell pool by in vitro stimulation
[43], there is a potential therapeutic application for these
cells in the treatment of patients with Goodpasture’s
disease. These approaches would reduce the need for
nonspecific immunosuppression with all the attendant
adverse effects.
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